FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006689588> ?p ?o ?g. }

• W3006689588 endingPage "735" @default.
• W3006689588 startingPage "730" @default.
• W3006689588 abstract "Four cycles of rituximab plus CHOP chemotherapy is as effective as 6 cycles in low-risk diffuse large B-cell lymphoma (DLBCL). Here we report a post-hoc analysis of a prospective clinical trial in patients with HIV-associated DLBCL and high-grade lymphoma treated with 4-6 cycles of EPOCH plus rituximab based a response-adapted treatment strategy. 106 evaluable patients with HIV-associated DLBCL or high-grade CD20-positive non-Hodgkin's lymphoma were randomized to receive rituximab (375 mg/m2) given either concurrently prior to each infusional EPOCH cycle, or sequentially (weekly for 6 weeks) following completion of EPOCH. EPOCH consisted of a 96-hour IV infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by IV bolus cyclophosphamide every 21 days for 4 to 6 cycles. Patients received 2 additional cycles of therapy after documentation of a complete response (CR) by computerized tomography after cycles 2 and 4. 64 of 106 evaluable patients (60%, 95% CI 50%, 70%) had a CR in both treatment arms. The 2-year event-free survival (EFS) rates were similar in the 24 patients with CR who received 4 or fewer EPOCH cycles (78%, 95% confidence intervals [55%, 90%]) due to achieving a CR after 2 cycles, compared with those who received 5-6 cycles of EPOCH (85%, 95% CI 70%, 93%) because a CR was first documented after cycle 4. A response-adapted strategy may permit a shorter treatment duration without compromising therapeutic efficacy in patients with HIV-associated lymphoma treated with EPOCH plus rituximab, which merits further evaluation in additional prospective trials. Clinical Trials.gov identifier NCT00049036." @default.
• W3006689588 created "2020-03-06" @default.
• W3006689588 creator A5012507181 @default.
• W3006689588 creator A5014543424 @default.
• W3006689588 creator A5043795032 @default.
• W3006689588 creator A5056409417 @default.
• W3006689588 creator A5059154513 @default.
• W3006689588 creator A5060718239 @default.
• W3006689588 creator A5063693935 @default.
• W3006689588 creator A5064702056 @default.
• W3006689588 creator A5068289010 @default.
• W3006689588 creator A5068593672 @default.
• W3006689588 creator A5085875361 @default.
• W3006689588 creator A5087813701 @default.
• W3006689588 creator A5091650487 @default.
• W3006689588 date "2020-02-27" @default.
• W3006689588 modified "2023-10-14" @default.
• W3006689588 title "Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma" @default.
• W3006689588 cites W1516310677 @default.
• W3006689588 cites W1577900120 @default.
• W3006689588 cites W1757115607 @default.
• W3006689588 cites W1844155670 @default.
• W3006689588 cites W1862918409 @default.
• W3006689588 cites W1912693401 @default.
• W3006689588 cites W1966831995 @default.
• W3006689588 cites W1978135177 @default.
• W3006689588 cites W1990827442 @default.
• W3006689588 cites W1996193488 @default.
• W3006689588 cites W2050529097 @default.
• W3006689588 cites W2079598348 @default.
• W3006689588 cites W2079801047 @default.
• W3006689588 cites W2093793136 @default.
• W3006689588 cites W2095678519 @default.
• W3006689588 cites W2097549829 @default.
• W3006689588 cites W2098488028 @default.
• W3006689588 cites W2126232974 @default.
• W3006689588 cites W2131047799 @default.
• W3006689588 cites W2135432883 @default.
• W3006689588 cites W2136060045 @default.
• W3006689588 cites W2138030132 @default.
• W3006689588 cites W2139789114 @default.
• W3006689588 cites W2144795394 @default.
• W3006689588 cites W2144957637 @default.
• W3006689588 cites W2153686208 @default.
• W3006689588 cites W2328638591 @default.
• W3006689588 cites W2502772544 @default.
• W3006689588 cites W2735487424 @default.
• W3006689588 cites W2797584152 @default.
• W3006689588 cites W2800320119 @default.
• W3006689588 cites W2803714962 @default.
• W3006689588 cites W2901132697 @default.
• W3006689588 cites W2976680230 @default.
• W3006689588 doi "https://doi.org/10.3324/haematol.2019.243386" @default.
• W3006689588 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7927888" @default.
• W3006689588 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32107337" @default.
• W3006689588 hasPublicationYear "2020" @default.
• W3006689588 type Work @default.
• W3006689588 sameAs 3006689588 @default.
• W3006689588 citedByCount "7" @default.
• W3006689588 countsByYear W30066895882021 @default.
• W3006689588 countsByYear W30066895882022 @default.
• W3006689588 countsByYear W30066895882023 @default.
• W3006689588 crossrefType "journal-article" @default.
• W3006689588 hasAuthorship W3006689588A5012507181 @default.
• W3006689588 hasAuthorship W3006689588A5014543424 @default.
• W3006689588 hasAuthorship W3006689588A5043795032 @default.
• W3006689588 hasAuthorship W3006689588A5056409417 @default.
• W3006689588 hasAuthorship W3006689588A5059154513 @default.
• W3006689588 hasAuthorship W3006689588A5060718239 @default.
• W3006689588 hasAuthorship W3006689588A5063693935 @default.
• W3006689588 hasAuthorship W3006689588A5064702056 @default.
• W3006689588 hasAuthorship W3006689588A5068289010 @default.
• W3006689588 hasAuthorship W3006689588A5068593672 @default.
• W3006689588 hasAuthorship W3006689588A5085875361 @default.
• W3006689588 hasAuthorship W3006689588A5087813701 @default.
• W3006689588 hasAuthorship W3006689588A5091650487 @default.
• W3006689588 hasBestOaLocation W30066895881 @default.
• W3006689588 hasConcept C121332964 @default.
• W3006689588 hasConcept C126322002 @default.
• W3006689588 hasConcept C1276947 @default.
• W3006689588 hasConcept C141071460 @default.
• W3006689588 hasConcept C143998085 @default.
• W3006689588 hasConcept C150846664 @default.
• W3006689588 hasConcept C2776694085 @default.
• W3006689588 hasConcept C2776755627 @default.
• W3006689588 hasConcept C2778119113 @default.
• W3006689588 hasConcept C2778476033 @default.
• W3006689588 hasConcept C2779338263 @default.
• W3006689588 hasConcept C2779429289 @default.
• W3006689588 hasConcept C2779725641 @default.
• W3006689588 hasConcept C2780317896 @default.
• W3006689588 hasConcept C2780653079 @default.
• W3006689588 hasConcept C71924100 @default.
• W3006689588 hasConcept C90924648 @default.
• W3006689588 hasConceptScore W3006689588C121332964 @default.
• W3006689588 hasConceptScore W3006689588C126322002 @default.
• W3006689588 hasConceptScore W3006689588C1276947 @default.
• W3006689588 hasConceptScore W3006689588C141071460 @default.

• next